Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting
Table 1
Demographic and clinical characteristics of patients at baseline by treatment regimen.
Characteristics
All patients (n = 112)
Treatment Regimens
p-value
LDV/SOF
SOF/VEL
(n = 87)
(n = 25)
Sex
0.629
Male
67 (59.8)
51 (58.6)
16 (64.0)
Female
45 (40.2)
36 (41.4)
9 (36.0)
Age (years)
60.7 (28-82)
61.6 (28-82)
57.2 (34-73)
0.076
Age group (Years)
0.234
< 65
74 (66.1)
55 (63.2)
19 (76.0)
≥ 65
38 (33.9)
32 (36.8)
6 (24.0)
BMI (Kg/m2)
29.0 (18.5-47.0)
28.7 (18.5-47.0)
30.2 (20-43)
0.242
BMI (Kg/m2)
0.488
< 30
65 (58.0)
52 (59.8)
13 (52.0)
≥ 30
47 (42.0)
35 (40.2)
12 (48.0)
HCV Genotype
0.131
1a
66 (58.9)
52 (59.8
14 (56.0)
1b
34 (30.4)
28 (32.2)
6 (24.0)
2
5 (4.5)
4 (4.6)
1 (4.0)
3
3 (2.7)
2 (2.3)
1 (4.0)
4
4 (3.6)
1 (1.1)
3 (12.0)
HCV RNA (IU/mL)
0.330
< 800,000
31 (27.7)
26 (29.9)
5 (20.0)
≥ 800,000
81 (72.3)
61 (70.1)
20 (80.0)
Prior treatment
0.086
Naïve
86 (76.8)
70 (80.5)
16 (64.0)
Experienced
26 (23.2)
17 (19.5)
9 (36.0)
Comorbidities
Diabetes
35 (31.3)
25 (28.7)
10 (40.0)
0.284
Hypertension
51 (45.5)
37 (42.5)
14 (56.0)
0.233
Coronary artery disease
12 (10.7)
9 (10.3)
3 (12.0)
0.728
Kidney disease
9 (8.0)
8 (9.2)
1 (4.0)
0.681
Chronic anemia
5 (4.5)
2 (2.3)
3 (12.0)
0.073
HIV seropositive
24 (21.4)
21 (24.1)
3 (12.0)
0.192
MELD score
0.195
< 10
62 (55.4)
51 (58.6)
11 (44.0)
≥ 10
50 (44.6)
36 (41.4)
14 (56.0)
Laboratory tests
Hemoglobin (g/dL)
13.4 (9.2-17.5)
13.5 (9.2-17.5)
13.0 (10.0-16.0)
0.278
Platelets (x1000/mL)
140.7 (23-316)
143.4 (43-316)
131.5 (23-216)
0.371
Albumin (g/dL)
3.5 (1.3-4.7)
3.5 (1.3-4.7)
3.5 (2.2-4.5)
0.899
AST (IU/L)
82.3 (16-210)
83.3 (16-210)
78.9 (20-179)
0.639
ALT (IU/L)
77.8 (12-264)
79.5 (12-264)
72.1 (13-200)
0.510
Bilirubin (mg/dL)
1.2 (0.3-4.9)
1.2 (0.3-4.9)
1.1 (0.5-3.2)
0.752
Data are presented as mean (range) or number (percentage). BMI, body mass index; HCV, hepatitis C virus; RNA, ribonucleic acid; APRI, AST-to-platelet ratio index; MELD, model for end-stage liver disease; AST, aspartate transaminase; and ALT, alanine transaminase.
